Pharma news in clinical trials, chronic condition management, and innovation from Q4 2017
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation.
Source: mobihealthnews - Category: Information Technology Source Type: news
More News: Abilify | Clinical Trials | Information Technology | Men | Pharmaceuticals | Schizophrenia